unknown
Stage
About
GlycoBAR develops and produces blood group antigen ligands using a proprietary biofermentation process to remove blood group antibodies and enable universal blood products such as plasma and platelets. They supply these antigen ligands and related reagents to medical and industrial customers.
Explore GlycoBAR's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.